Stanford-Developed “Decoy Molecules” Can Halt the Spread of Cancer

Multiple myeloma is a kind of cancer that develops in a type of white blood cell known as a plasma cell.

Both MM and DLBCL are cancers that arise from the body’s B cells, which make antibodies. Less than 60% of patients who have one of these conditions will survive five years. Miao co-led the new research with Stanford University’s Dr. Kaushik Thakkar and Professor Amato J. Giaccia, who currently works at theOxford Institute for Radiation Oncology. The Medical Research Council UK provided partial funding for the research.

BCMA is a B cell surface receptor that binds to both APRIL and BAFF. Miao and colleagues investigated whether a soluble version of BCMA, unattached to the B cell surface, would act as a “decoy receptor” to mop up excess APRIL and BAFF and prevent these proteins from driving the growth of cancerous B cells.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

A new small and less costly molecule could make immunotherapy available to all cancer patientsResearchers came up with a small molecule, which will be a less costly and more effective alternate to an antibody that can treat various types of cancers.
Source: IntEngineering - 🏆 287. / 63 Read more »